For richer charts and full features, open SpikePanel on desktop.
Graded daily on value C+, growth A+, profitability B+, momentum A+, revisions A-. Sector-relative, identical for every user.
Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $CDNA are available with SpikePanel Pro.
Key events, in time order
EPS $0.70 beats estimates, driven by testing volume growth and oncology addition
Q3 2026 总营收为 $139 million,同比增长 39%,其中测试服务营收 $119 million,同比增长 65%。
Company announcement highlights clinical data supporting AlloSure Kidney's prognostic value in borderline rejection or TCMR patients.
Company releases Q2 results, drawing market attention and stock rise.
非 GAAP 毛利率提升至 74%,调整后 EBITDA 增长 $19 百万至 $25 百万,占营收 19%。
None yet
None yet
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice